Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL823816 | 0.83 | TSHR (0.33) | TSHRKIF11 | |
| SCHEMBL19250151 | 0.83 | — | — | |
| SCHEMBL19919144 | 0.78 | — | — | |
| SCHEMBL12459213 | 0.77 | GABRA1 (0.33) | — | |
| SCHEMBL21265942 | 0.77 | LMNA (0.30) | — | |
| SCHEMBL21316603 | 0.77 | — | — | |
| SCHEMBL2616425 | 0.77 | P2RX7 (0.32) | KIF11 | |
| SCHEMBL19053356 | 0.77 | — | — | |
| SCHEMBL25587240 | 0.77 | — | — | |
| SCHEMBL26152957 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321063-A1 | COMPOSITIONS AND METHODS TO REDUCE NEUROINFLAMMATION | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2023-10-12 | — | — | US | disclosed |
| US-20180055828-A1 | KINASE MODULATION, AND INDICATIONS THEREFOR | DAIICHI SANKYO, INC. | 2018-03-01 | — | — | US | disclosed |
| US-9730918-B2 | Kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9730918-B2 | Kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160243092-A1 | KINASE MODULATION, AND INDICATIONS THEREFOR | DAIICHI SANKYO, INC. | 2016-08-25 | — | — | US | disclosed |
| US-9358235-B2 | Kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9096593-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140045840-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140037617-A1 | KINASE MODULATION, AND INDICATIONS THEREFOR | DAIICHI SANKYO, INC. | 2014-02-06 | — | — | US | disclosed |
| US-20110112127-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140037617-A1 | KINASE MODULATION, AND INDICATIONS THEREFOR | FLT3, FLT4, FLT1 | TSHR 1599/4885KIF11 1734/4885 |
| US-20110112127-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | KIT, FLT3, BRAF | TSHR 1633/4885KIF11 1511/4885 |
| US-20230321063-A1 | COMPOSITIONS AND METHODS TO REDUCE NEUROINFLAMMATION | CXCR3, MTOR, CX3CR1 | TSHR 4097/4885KIF11 3547/4885 |
| US-20160243092-A1 | KINASE MODULATION, AND INDICATIONS THEREFOR | FLT3, FLT4, FLT1 | TSHR 1599/4885KIF11 1734/4885 |
| US-20180055828-A1 | KINASE MODULATION, AND INDICATIONS THEREFOR | FLT3, FLT4, FLT1 | TSHR 1599/4885KIF11 1734/4885 |
| US-20140045840-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | KIT, FLT3, BRAF | TSHR 1633/4885KIF11 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.